{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:34:17Z","timestamp":1761824057863},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5]]},"abstract":"<jats:p>Relapsed acute myeloid leukemia presenting as an isolated central nervous system myeloid sarcoma (CNS MS) is very rare and generally entails poor outcomes. CNS MS treatment is not well defined and can include systemic chemotherapy, intrathecal chemotherapy, radiation therapy, or hematopoietic stem cell transplant. Thiotepa, vinorelbine, topotecan, and clofarabine (TVTC) has been successful for reinduction therapy in relapsed\/refractory leukemia to induce remission before hematopoietic stem cell transplant. There is no published evidence of TVTC being utilized for CNS MS. In this series, we report 2 symptomatic patients with isolated CNS MS at relapse who demonstrated near complete resolution after reinduction with TVTC and additional intrathecal chemotherapy.<\/jats:p>","DOI":"10.1097\/mph.0000000000001383","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T10:36:27Z","timestamp":1545042987000},"page":"319-321","source":"Crossref","is-referenced-by-count":2,"title":["Successful Treatment of Relapsed Pediatric Acute Myeloid Leukemia Presenting as Central Nervous System Myeloid Sarcoma: A Single-Institution Case Series"],"prefix":"10.1097","volume":"42","author":[{"given":"Kenneth E.","family":"Bujold","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology-Oncology, Baystate Children\u2019s Hospital, Springfield, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Smita","family":"Dandekar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology-Oncology, Penn State Milton S. Hershey Medical Center, Hershey, PA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mustafa","family":"Barbour","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology-Oncology, University of Louisville, Louisville, KY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"e26612","DOI":"10.1002\/pbc.26612","article-title":"Central nervous system disease in pediatric acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"64","author":"Johnston","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pbc.23201","article-title":"Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children\u2019s Oncology Group","volume":"58","author":"Johnston","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/mpo.10069","article-title":"Isolated extramedullary relapse in acute myeloid leukemia: a retrospective analysis","volume":"38","author":"Ginsberg","year":"2002","journal-title":"Med Pediatr Oncol"},{"key":"R4-20230918","doi-asserted-by":"crossref","DOI":"10.5812\/ijp.1711","article-title":"Extramedullary relapse of acute myeloid and lymphoid leukemia in children: a retrospective analysis","author":"Young Kim","year":"2016","journal-title":"Iran J Pediatr"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"9172","DOI":"10.1200\/JCO.2005.02.7482","article-title":"Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia","volume":"23","author":"Johnston","year":"2005","journal-title":"J Clin Oncol"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"177","DOI":"10.5505\/tjh.2012.65002","article-title":"Cerebellar granulocytic sarcoma: a case report","volume":"29","author":"Baytan","year":"2012","journal-title":"Turk J Haematol"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S0145-2126(01)00068-6","article-title":"Cerebellar granulocytic sarcoma in an infant with CD56+ acute monoblastic leukemia","volume":"25","author":"Psiachou-Leonard","year":"2001","journal-title":"Leuk Res"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/08880018.2017.1360970","article-title":"Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia","volume":"34","author":"Messinger","year":"2017","journal-title":"Pediatr Hematol Oncol"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/ped.13378","article-title":"Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia","volume":"59","author":"Nakayama","year":"2017","journal-title":"Pediatr Int"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1111\/bjh.12947","article-title":"How I treat paediatric relapsed acute myeloid leukaemia","volume":"166","author":"Kaspers","year":"2014","journal-title":"Br J Haematol"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1002\/pbc.24789","article-title":"Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia","volume":"61","author":"Shukla","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s40272-013-0048-y","article-title":"Relapsed and refractory pediatric acute myeloid leukemia: current and emerging treatments","volume":"16","author":"Davila","year":"2014","journal-title":"Paediatr Drugs"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/pbc.25117","article-title":"A phase 2 study of bortezomib combined with either idarubicin\/cytarabine or cytarabine\/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children\u2019s Oncology Group","volume":"61","author":"Horton","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.2012.43.7384","article-title":"Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group","volume":"31","author":"Kaspers","year":"2013","journal-title":"J Clin Oncol"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/era.12.1","article-title":"Pediatric acute myeloid leukemia","volume":"12","author":"Kaspers","year":"2012","journal-title":"Expert Rev Anticancer Ther"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/pbc.22612","article-title":"Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study","volume":"55","author":"Gorman","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2009-04-215152","article-title":"Novel prognostic subgroups in childhood 11q23\/MLL-rearranged acute myeloid leukemia: results of an international retrospective study","volume":"114","author":"Balgobind","year":"2009","journal-title":"Blood"},{"key":"R18-20230918","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26782","article-title":"Central nervous system disease in pediatric acute myeloid leukemia","volume":"64","author":"Gruber","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/BF00688317","article-title":"Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors","volume":"37","author":"Baker","year":"1995","journal-title":"Cancer Chemother Pharmacol"},{"key":"R20-20230918","first-page":"736","article-title":"Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa","volume":"49","author":"Heideman","year":"1989","journal-title":"Cancer Res"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001383","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:44:13Z","timestamp":1695012253000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001383","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]}}}